Toxicological Research

Korean Society of Toxicology & Korea Environmental Mutagen Society (한국독성학회)
권호 표지
DOI QR코드

DOI QR Code

In Vitro Evaluation of Antimicrobial Activity of Lactic Acid Bacteria against Clostridium difficile

  • Received : 2013.06.07
  • Accepted : 2013.06.12
  • Published : 2013.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Clostridium difficile infection (CDI) has become a significant threat to public health. Although broad-spectrum antibiotic therapy is the primary treatment option for CDI, its use has evident limitations. Probiotics have been proved to be effective in the treatment of CDI and are a promising therapeutic option for CDI. In this study, 4 strains of lactic acid bacteria (LAB), namely, Lactobacillus rhamnosus (LR5), Lactococcuslactis (SL3), Bifidobacterium breve (BR3), and Bifidobacterium lactis (BL3) were evaluated for their anti-C. difficile activity. Co-culture incubation of C. difficile ($10^6$ and $10^{10}$ CFU/ml) with each strain of LAB indicated that SL3 possessed the highest antimicrobial activity over a 24-hr period. The cell-free supernatants of the 4 LAB strains exhibited $MIC_{50}$ values between 0.424 mg/ml (SL3) and 1.318 (BR3) mg/ml. These results may provide a basis for alternative therapies for the treatment of C. difficile-associated gut disorders.

Keywords

References

  1. Aslam, S., Hamill, R.J. and Musher, D.M. (2005) Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect. Dis., 5, 549-557. https://doi.org/10.1016/S1473-3099(05)70215-2
  2. Nelson, R. (2007) Antibiotic treatment for Clostridium difficile- associated diarrhea in adults. Cochrane Database Syst. Rev., 18, CD004610.
  3. Bartlett, J.G. (2010) Clostridium difficile: progress and challenges. Ann. N. Y. Acad. Sci., 1213, 62-69. https://doi.org/10.1111/j.1749-6632.2010.05863.x
  4. Ohl, M.E., Stevermer, J.J., Meadows, S., Tribuna, J. and Chek, K. (2005) What are effective therapies for Clostridium difficile-associated diarrhea? J. Fam. Pract., 54, 176-178.
  5. Dethlefsen, L., Huse, S., Sogin, M.L. and Relman, D.A. (2008) The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol., 6, e280. https://doi.org/10.1371/journal.pbio.0060280
  6. Kang, B.S., Seo, J.G., Lee, G.S., Kim, J.H., Kim, S.Y., Han, Y.W., Kang, H., Kim, H.O., Rhee, J.H., Kang, B.S., Seo, J.G., Lee, G.S., Kim, J.H., Kim, S.Y., Han, Y.W., Kang, H., Kim, H.O., Rhee, J.H., Chung, M.J. and Park, Y.M. (2009) Antimicrobial activity of enterocins from Enterococcus faecalis SL-5 against Propionibacterium acnes, the causative agent in acne vulgaris, and its therapeutic effect. J. Microbiol., 47, 101-109. https://doi.org/10.1007/s12275-008-0179-y
  7. Forestier, C., De Champs, C., Vatoux, C. and Joly, B. (2001) Probiotic activities of Lactobacillus casei rhamnosus: in vitro adherence to intestinal cells and antimicrobial properties. Res. Microbiol., 152, 167-173. https://doi.org/10.1016/S0923-2508(01)01188-3
  8. Guarner, F. and Schaafsma, G.J. (1998) Probiotics. Int. J. Food Microbiol., 39, 237-238. https://doi.org/10.1016/S0168-1605(97)00136-0
  9. Jin, L.Z., Ho, Y.W. Abdullah, N., Ali, M.A. and Jalaludin, S. (1996) Antagonistic effects of intestinal Lactobacillus isolates on pathogens of chicken. Lett. Appl. Microbiol., 23, 67-71. https://doi.org/10.1111/j.1472-765X.1996.tb00032.x
  10. Aroutcheva, A., Gariti, D., Simon, M., Shott, S., Faro, J., Simoes, J.A., Gurguis, A. and Faro, S. (2001) Defense factors of vaginal lactobacilli. Am. J. Obstet. Gynecol., 185, 375-379. https://doi.org/10.1067/mob.2001.115867
  11. Surawicz, C.M., McFarland, L.V., Greenberg, R.N., Rubin, M., Fekety, R., Mulligan, M.E., Garcia, R.J., Brandmarker, S., Bowen, K., Borjal, D. and Elmer, G.W. (2000) The search for a better treatment for recurrent Clostridium difcile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin. Infect. Dis., 31, 1012-1017. https://doi.org/10.1086/318130
  12. McFarland, L.V., Surawicz, C.M., Greenberg, R.N., Fekety, R., Elmer, G.W., Moyer, K.A., Melcher, S.A., Bowen, K.E., Cox, J.L., Noorani, Z., Harrington, G., Rubin, M. and Greenwald, D. (1994) A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difcile disease. JAMA, 271, 1913-1918. https://doi.org/10.1001/jama.1994.03510480037031
  13. Pochapin, M. (2000) The effect of probiotics on Clostridium difcile diarrhea. Am. J. Gastroenterol., 95, S11-S13. https://doi.org/10.1016/S0002-9270(99)00809-6
  14. Wullt, M., Hagslatt, M.L. and Odenholt, I. (2003) Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difcile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand. J. Infect. Dis., 35, 365-367. https://doi.org/10.1080/00365540310010985
  15. Lawrence, S.J., Korzenik, J.R. and Mundy, L.M. (2005) Probiotics for recurrent Clostridium difcile disease. J. Med. Microbiol., 54, 905-906. https://doi.org/10.1099/jmm.0.46096-0
  16. Guandalini, S. (2006) Probiotics for children: use in diarrhea. J. Clin. Gastroenterol., 40, 244-248. https://doi.org/10.1097/00004836-200603000-00016
  17. Katz, J.A. (2006) Probiotics for the prevention of antibioticassociated diarrhea and Clostridium difficile diarrhea. J. Clin. Gastroenterol., 40, 249-255. https://doi.org/10.1097/00004836-200603000-00017
  18. Fooks, L.J., Fuller, R. and Gibson, G.R. (1999) Prebiotics, probiotics and human gut microbiology. Int. Dairy J., 9, 53-61. https://doi.org/10.1016/S0958-6946(99)00044-8
  19. Cha, B.K., Jung, S.M., Choi, C.H., Song, I.D., Lee, H.W., Kim, H.J., Hyuk, J., Chang, S.K., Kim, K., Chung, W.S. and Seo, J.G. (2012) The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J. Clin. Gastroenterol., 46, 220-227. https://doi.org/10.1097/MCG.0b013e31823712b1
  20. Clinical and Laboratory Standards Institute. (2006) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically (7th ed.), Clinical and Laboratory Standards Institute, Wayne, PA, pp. 1-49.
  21. Folkers, B.L., Schuring, C., Essmann, M. and Larsen, B. (2010) Quantitative real time PCR detection of Clostridium difficile growth inhibition by probiotic bacteria. N. Am. J. Med. Sci., 2, 5-10.
  22. Trejo, F.M., Perez, P.F. and De Antoni, G.L. (2010) Co-culture with potentially probiotic microorganisms antagonises virulence factors of Clostridium difficile in vitro. Antonie van Leeuwenhoek, 98, 19-29. https://doi.org/10.1007/s10482-010-9424-6
  23. Gonzalez, L., Sandoval, H., Sacristan, N., Castro, J.M., Fresno, J.M. and Tornadijo, M.E. (2007) Identification of lactic acid bacteria isolated from Genestoso cheese throughout ripening and study of their antimicrobial activity. Food Control, 18, 716-722. https://doi.org/10.1016/j.foodcont.2006.03.008
  24. Bartoloni, A., Mantella, A., Goldstein, B.P., Dei, R., Benedetti, M., Sbaragli, S. and Paradisi, F. (2004) In-vitro activity of nisin against clinical isolates of Clostridium difficile. J. Chemother., 16, 119-121. https://doi.org/10.1179/joc.2004.16.2.119
  25. Kojic, M., Svicevic, J., Banina, A. and Topisirovic, L. (1991) Bacteriocin-producing strain of Lactococcus lactis subsp. diacitilactis S50. Appl. Environ. Microbiol., 57, 1835-1837.
  26. Kozak, W., Bardowski, J. and Dobrzansky, W.T. (1978) Lactostrepcins- acid bacteriocin produced by lactic streptococci. J. Dairy Res., 45, 247-257. https://doi.org/10.1017/S0022029900016423
  27. De Vuyst, L. (1994) Nisin production variability between natural Lactococcus lactis subsp. Lactis strains. Biotechnol. Lett., 16, 287-292. https://doi.org/10.1007/BF00134627
  28. Mulligan, M.E., Rolfe, R.D., Finegold, S.M. and George, W.L. (1979) Contamination of a hospital environment by Clostridium difficile. Curr. Microbiol., 3, 173-175. https://doi.org/10.1007/BF02601862

Cited by

  1. Microorganisms with Claimed Probiotic Properties: An Overview of Recent Literature vol.11, pp.5, 2014, https://doi.org/10.3390/ijerph110504745
  2. A Probiotic Preparation Duolac-Gold Ameliorates Dextran Sulphate Sodium-induced Mouse Colitis by Downregulating the Expression of IL-6 vol.30, pp.1, 2014, https://doi.org/10.5487/TR.2014.30.1.027
  3. Lactic acid bacteria from traditionally processed corn beer and palm wine against selected food-borne pathogens isolated in south west region of Cameroon vol.10, pp.30, 2016, https://doi.org/10.5897/AJMR2016.8143
  4. Effect of Bifidobacterium upon Clostridium difficile Growth and Toxicity When Co-cultured in Different Prebiotic Substrates vol.7, pp.1664-302X, 2016, https://doi.org/10.3389/fmicb.2016.00738
  5. A common bacterial metabolite elicits prion-based bypass of glucose repression vol.5, pp.2050-084X, 2016, https://doi.org/10.7554/eLife.17978
  6. Therapeutic effects of probiotics on neurotoxicity induced by clindamycin and propionic acid in juvenile hamsters pp.1573-7365, 2018, https://doi.org/10.1007/s11011-018-0284-5
  7. Encapsulating Viability of Multi-strain Lactobacilli as Potential Probiotic in Pigs pp.1867-1314, 2019, https://doi.org/10.1007/s12602-018-9418-7